Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. 2013

Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
FGM, Center of Internal Medicine, Department of Nephrology and Rheumatology, Müllheim, Germany.

During Fabry disease, progressive glycosphingolipid deposition in the kidney causes gradual deterioration of renal function with proteinuria, uremia and hypertension. This results in end-stage renal disease (ESRD) which is one of the leading causes of morbidity and premature mortality in affected patients. Given the excellent graft and patient survival generally nowadays, kidney transplantation is the first choice to correct renal dysfunction and improve the overall prognosis of patients with renal failure because of Fabry disease. The benefit of enzyme-replacement therapy (ERT) in kidney transplanted Fabry patients has been controversially discussed and long-term trials focusing on the effectiveness of agalsidase in this patient population are needed.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000519 alpha-Galactosidase An enzyme that catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-galactosides including galactose oligosaccharides, galactomannans, and galactolipids. Beano,Melibiase,alpha-D-Galactopyranosidase,alpha-D-Galactosidase,alpha-Galactisidase,alpha-Galactosidase A,alpha-Galactosidases,alpha D Galactopyranosidase,alpha D Galactosidase,alpha Galactisidase,alpha Galactosidase,alpha Galactosidase A,alpha Galactosidases
D000795 Fabry Disease An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders. Anderson-Fabry Disease,Angiokeratoma Corporis Diffusum,Angiokeratoma Diffuse,Angiokeratoma, Diffuse,Ceramide Trihexosidase Deficiency,Fabry's Disease,GLA Deficiency,Hereditary Dystopic Lipidosis,alpha-Galactosidase A Deficiency,alpha-Galactosidase A Deficiency Disease,Anderson Fabry Disease,Deficiency, Ceramide Trihexosidase,Deficiency, GLA,Deficiency, alpha-Galactosidase A,Diffuse Angiokeratoma,Lipidosis, Hereditary Dystopic,alpha Galactosidase A Deficiency,alpha Galactosidase A Deficiency Disease
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D056947 Enzyme Replacement Therapy Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE). Enzyme Replacement Therapies,Replacement Therapies, Enzyme,Replacement Therapy, Enzyme,Therapies, Enzyme Replacement,Therapy, Enzyme Replacement
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
February 2004, Kidney international,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
March 1973, Birth defects original article series,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
May 2007, Journal of the American Society of Nephrology : JASN,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
June 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
November 2003, Journal of the European Academy of Dermatology and Venereology : JEADV,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
February 2010, Clinical journal of the American Society of Nephrology : CJASN,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
January 2001, Journal of inherited metabolic disease,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
April 2004, Kidney international,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
August 2005, Molecular neurobiology,
Markus Cybulla, and Christine Kurschat, and Michael West, and Kathy Nicholls, and Joan Torras, and Gere Sunder-Plassmann, and Sandro Feriozzi
January 2004, Acta dermato-venereologica,
Copied contents to your clipboard!